ERBB2 and breast cancer: Regarding BC subtypes, 33% and 37% of patients had Luminal A-like and Luminal B-like BC, respectively, 16% of patients had HER2+ BC (either HR+ or HR–), and 13% of patients had triple-negative BC (TNBC).